Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank –
Summary
26, 2022-- (Nasdaq: ISEE) announced today that it has entered into a term loan debt financing facility with (NYSE: HTGC) and providing the Company with total borrowing capacity of up to in non-dilutive debt financing.We are grateful to secure this non-dilutive financing as it further strengthens our balance sheet and provides financial flexibility as we look to fund the potential commercial launch of Zimura\xae (avacincaptad pegol) in geographic atrophy (GA) in , subject to regulatory approval, stated , Chief Financial Officer of . This significant capital commitment from Hercules will help continue developing Zimura as a potential treatment of choice for GA, added , Managing Director at .Iveric Bio is doing important work to advance potential treatments for GA and other retinal diseases, said , Managing Director of Life Sciences & Healthcare at . served as legal counsel to and in connection with the facility.About is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. In this press release, the Companys forward looking statements include statements about its expectations regarding its development and regulatory strategy for Zimura, including the timing of receipt of topline data from the GATHER2 clinical trial, its ability to use its completed GATHER1 trial as a Phase 3 trial for purposes of seeking regulatory approval, the potential commercial launch of Zimura, and the potential utility of Zimura for treating geographic atrophy (GA), if approved.